MedTrace Logo

Lung Deposition Via Different Inhalation Devices

NCT00975754 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-12-11

No results posted yet for this study

Summary

The purpose of this study is to assess the deposition of budesonide to the lung after inhalation with 5 different devices and to relate the findings to in vitro properties of inhaled budesonide.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Pulmicort pMDI HFA

Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations

DRUG

Budesonide pMDI HFA

Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations

DRUG

Pulmicort Repulses

Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations

DRUG

Pulmicort Turbohaler

Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations

Sponsors & Collaborators

Principal Investigators

  • Carin Jorup · AstraZeneca R&D Lund, Sweden

  • Pia Lena Berg · Clinical Pharmacology Unit, AstraZeneca R&D Lund, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Completion
2009-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00975754 on ClinicalTrials.gov